Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Cynomolgus PDCD1 /PD1 Protein, With C-Fc Tag, 100µg  

Recombinant Cynomolgus PDCD1 /PD1 Protein, With C-Fc Tag, 100µg

Recombinant Cynomolgus PDCD1 /PD1 Protein, With C-Fc Tag (Cyno PDCD1 / PD1 Fc Chimera) Pro 21 - Gln 167 was produced in human HEK293 cells

Synonym
recombinant protein PDCD1, PD1, CD279, SLEB2, hPD-1, hPD-l

More details

PD1-C5254-100

Availability: within 7 days

360,00 €

Background
Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.

Source
Recombinant Cynomolgus PDCD1 /PD1 Protein, With C-Fc Tag (Cyno PDCD1 / PD1 Fc Chimera) Pro 21 - Gln 167 (Accession # ABR15751.1) was produced in human 293 cells

Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 42.6 kDa. The protein migrates as 53-60 kDa under reducing (R) condition (SDS-PAGE) due to different glycosylation.

Endotoxin
Less than 1.0 EU per μg of the Cyno PDCD1 / PD1 Fc Chimera by the LAL method.

Purity
>90% as determined by SDS-PAGE.

SDS-Page
Cynomolgus PD-1, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

Bioactivity
Immobilized Human PD-L1, Mouse Fc Tag (Cat. No. PD1-H52A3) at 5 μg/mL (100 μL/well) can bind Cynomolgus PD-1, Fc Tag (Cat. No. PD1-C5254) with a linear range of 3-33 ng/mL (QC tested).
Immobilized Cynomolgus PD-1, Fc Tag (Cat. No. PD1-C5254) at 2 μg/mL (100 μL/well) can bind Nivolumab with a linear range of 0.1-3 ng/mL (Routinely tested).

Formulation
Lyophilized from 0.22 μm filtered solution in 50 mM tris, 100 mM glycine, pH7.5. Normally Mannitol or Trehalose are added as protectants before lyophilization.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for or 3 months (-20°C to -70°C).

References

(1) Ishida Y., et al., 1992, EMBO J. 11 (11): 3887–95.
(2) Blank C., et al., 2007, Cancer Immunol. Immunother. 56 (5): 739–45.
(3) Agata Y., et al., 1996, Int. Immunol. 8 (5): 765–72.
(4) Freeman GJ., et al., 2000, J. Exp. Med. 192 (7): 1027–34.
(5) Latchman Y., et al., 2001, Nat. Immunol. 2 (3): 261–8.
(6) Yamazaki T., et al., 2002, J. Immunol. 169 (10): 5538–45. (HEK293)